ArticleProtein science : a publication of the Protein Society2026
MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Multiple sclerosis (MS) arises from an autoimmune response in which the immune system erroneously targets myelin autoantigens within the central nervous system, leading to myelin degradation and subsequent neurological dysfunction. Identifying myelin autoantigenic peptides (MAPs) is therefore critical for understanding MS pathogenesis and developing targeted therapies; however, conventional experimental approaches remain time-consuming and costly. Thus, computational methods that can perform in silico screening of T cell-specific MAP in MS (MAPMSs) using only peptide sequences are highly desirable. Existing computational methods primarily rely on a single modality, which often fails to capture key information of MAPMSs, leading to limited sequence representation and generalization ability. To address this limitation, we propose MIF-MAPMS, a novel multimodal information fusion framework that leverages multimodal information, including peptide format and SMILEs notation, for accurate MAPMS identification. This novel framework processes different modalities of compositional descriptors, molecular fingerprints, ESM-2 embeddings, and Mol2V embeddings using specific deep learning methods, leading to enriched MAPMS representation. Subsequently, the extracted embeddings are fused and passed through a multilayer perceptron (MLP), followed by a fully connected neural network for MAPMS identification. Both cross-validation and independent test results show that MIF-MAPMS attains significant improvements in MAPMS identification over the benchmark main and alternative datasets, with Matthew's correlation coefficient (MCC) of 0.931-0.968 and 0.812-0.928, providing 5.78%-8.04% and 1.22%-2.98% increases, respectively, compared to the existing method. Ablation studies further confirm the necessity of multimodal information fusion in improving MAPMS representation and the model's predictive performance. All codes and datasets are freely available online at https://github.com/lawankorn-m/MIF-MAPMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.